Advanced SearchSearch Tips
Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma
Mansour, Sahar F; Atwa, Maha M;
  PDF(new window)
Background: Biomarkers in breast neoplasms provide invaluable information regarding prognosis and help determining the optimal treatment. We investigated the possible correlation between cancer stem cell (CSC) markers (CD133, and ALDH1) in invasive ductal breast carcinomas with some clinicopathological parameters. Aim: To assess the correlation between expression of cancer stem cell (CSC) markers (CD133, and ALDH1) and clinicopathological parameters of invasive ductal breast carcinomas. Materials and Methods: Immunohistochemical analysis of CD133 and ALDH1 was performed on a series of 120 modified radical mastectomy (MRM) specimens diagnosed as invasive ductal breast carcinoma. Results: Expression of both CD133 and ALDH1 was significantly changed and related to tumor size, tumor stage (TNM), and lymph node metastasis. A negative correlation between CD133 and ALDH1 was found. Conclusions: Detecting the expression of CD133 and ALDH1 in invasive ductal breast carcinomas may be of help in more accurately predicting the aggressive properties and determining the optimal treatment.
Breast carcinoma;cancer stem cell markers;CD133;ALDH1;
 Cited by
Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer",;;

Journal of Breast Cancer, 2016. vol.19. 1, pp.96-98 crossref(new window)
Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari",;;

Journal of Breast Cancer, 2016. vol.19. 3, pp.336-338 crossref(new window)
Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari", Journal of Breast Cancer, 2016, 19, 3, 336  crossref(new windwow)
miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer, Oncology Reports, 2017, 37, 2, 1093  crossref(new windwow)
miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer, Oncology Reports, 2017, 37, 5, 2720  crossref(new windwow)
Epithelial–mesenchymal transition and gastric cancer stem cell, Tumor Biology, 2017, 39, 5, 101042831769837  crossref(new windwow)
miR-196a-5p modulates gastric cancer stem cell characteristics by targeting Smad4, International Journal of Oncology, 2017, 50, 6, 1965  crossref(new windwow)
Alison MR, Guppy NJ, Lim SM, et al (2010). Finding cancer stem cells, are aldehyde dehydrogenases fit for purpose?. J Pathol, 222, 335-44. crossref(new window)

Bertolini G, Roz L, Perego P, et al (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U.S.A, 106, 16281-6. crossref(new window)

Bexell D, Gunnarsson S, Siesjo P, et al (2009). CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. International J Cancer, 125, 15-22. crossref(new window)

Bozzi F, Conca E, Manenti G, et al (2011). High CD133 expression levels in gastrointestinal stromal tumors. Cytometry B Clin Cytom, 80, 238-47.

Charafe-Jauffret E, Ginestier C, Iovino F, et al (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res, 16, 45-55. crossref(new window)

Clark MF, and Fuller M (2006). Stem cells and cancer, Two faces of eve. Cell, 124, 1111-5. crossref(new window)

Clevers H (2011). The cancer stem cell, Premises, promises and challenges. Nat Med, 17, 313-9. crossref(new window)

Deng S, Yang X, Lassus H, et al (2010). Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, 10277. crossref(new window)

Di Bonito M, Collina F, Cantile M, et al (2012). Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast carcinoma, a correlative study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis. J Breast Cancer, 15, 15-23. crossref(new window)

Douville J, Beaulieu R & Balicki D (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev, 18, 17-25. crossref(new window)

Ferlay J, Soerjomataram I, Ervik M, et al (2013). Cancer Incidence and Mortality Worldwide (2013). IARC Cancer Base No. 11 Lyon, France, International Agency for Research on Cancer. GLOBOCAN v1.0

Gaur P, Sceusi EL, Samuel S, et al (2011). Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology, 141, 1728-37. crossref(new window)

Huang EH, Hynes MJ, Zhang T, et al (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res, 69, 3382-9. crossref(new window)

Ibrahim A, Khaled H, Mikhail N, et al (2014). Cancer incidence in Egypt, results of the national population-based cancer registry program. J Cancer Epidemiology.

Ieni A, Giuffre G, Adamo V, et al (2011). Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res, 31, 1315-20.

Jiang F, Qiu Q, Khanna A, et al (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res, 7, 330-8. crossref(new window)

Keymoosi H, Gheytanchi E, Asgari M, et al (2014). ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev, 15, 2013-20. crossref(new window)

Lamy PJ, Martin PM, Romieu G, et al (2013). Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for earlystage breast cancer, a systematic review. J Natl Cancer Inst, 105, 149.

Liao Y, Hu X, Huang X, et al (2010). Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biological & Pharmaceutical Bulletin, 33, 738-742. crossref(new window)

Madjd Z, Ramezani B, Molanae S, et al (2012). High Expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev, 13, 2973-8. crossref(new window)

Meacham C, and Morrison S (2013), Tumor heterogeneity and cancer cell plasticity. Nature, 501, 328-37. crossref(new window)

Meyer M, Fleming J, Ali M, et al (2009). Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 11, R82. crossref(new window)

Mills J, and Shivdasani R (2011). Gastric epithelial stem cells. Gastroenterology, 140, 412-24. crossref(new window)

Morimoto K, Kim S, Tanei T, et al (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 100, 1062-8. crossref(new window)

Navin N, Kendall J, Troge J, et al (2011). Tumor evolution inferred by single-cell sequencing. Nature, 472, 90-4. crossref(new window)

Ohi Y, Umekita Y, Yoshioka T, et al (2011). Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology, 59, 776-80 crossref(new window)

Park SY, Lee HE, Li H, et al (2010). Heterogeneity for stem cellrelated markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res, 16, 876-87. crossref(new window)

Rao Q, Yao T, Zhang B, et al (2012). Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev, 13, 1325-31. crossref(new window)

Rasha M Abd El Atti, Riham M Abu-Zeid (2012). CD133 and FGF7. Egyptian Journal of Pathology, 32, 142-9. crossref(new window)

Resetkova E, Reis-Filho J, Jain R, et al (2010). Prognostic impact of ALDH1 in breast cancer, a story of stem cells and tumor microenvironment. Breast Cancer Res Treat, 123, 97-108. crossref(new window)

Reya T, Morrison S, Clarke M, et al (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11. crossref(new window)

Sakakibara M, Fujimori T, Miyoshi T, et al (2012). Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Cancer, 118, 3899-910. crossref(new window)

Saricanbaz I, Karahacioglu E, Ekinci O, et al (2014). Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev, 15, 8215-9. crossref(new window)

Satpute P, Hazarey V, Ahmed R et al (2013). Cancer stem cells in head and neck squamous cell carcinoma, a review. Asian Pac J Cancer Prev, 14, 5579-87. crossref(new window)

Schneider M, Huber J, Hadaschik B, et al (2012). Characterization of colon cancer cells, a functional approach characterizing CD133 as a potential stem cell marker," BMC Cancer, 12, 96. crossref(new window)

Shi C, Tian R, Wang M, et al (2010). CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther, 10, 1182-90. crossref(new window)

Shimada Y, Ishii G, Nagai K et al (2009). Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci, 100, 2054-9. crossref(new window)

Tessari A, Palmieri D, Di Cosimo S (2013). Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med, 7, 1-19.

Timothy E, Wang D, Harki D (2013). Cell surface markers of cancer stem cells, diagnostic macromolecules and targets for drug delivery. Drug Delivery and Translational Research, 3, 121-42. crossref(new window)

Tirino V, Camerlingo R, Franco R, et al (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg, 36, 446-53. crossref(new window)

Turner N, Pestrin M, Galardi F, et al (2014). Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel), 6, 684-707. crossref(new window)

Visvader J, and Lindeman G (2008). Cancer stem cells in solid tumours, Accumulating evidence and unresolved questions. Nat Rev Cancer, 8, 755-68. crossref(new window)

Wang K, Liu L, Zhang T, et al (2011). Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine, 6, 3207-18.

Wright M, Calcagno A, Salcido C, et al (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10, 10.

Wu Y, and Wu P (2009). CD133 as a marker for cancer stem cells, progresses and concerns. Stem Cells Dev, 18, 1127-34. crossref(new window)

Yan X, Ma L, Yi D, et al (2011). A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A, 108, 1591-6. crossref(new window)

Zhao P, Lu Y, Jiang X, et al (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci, 102, 1107-11. crossref(new window)

Zobalova R, Prokopova K, Stantic M, et al (2011). The Potential role of CD133 in immune surveillance and apoptosis, a mitochondrial connection? Antioxidants & Redox Signaling, 15, 2989-3002. crossref(new window)